Abraxis Pharmaceutical
As of the edition of 20 October 2026, Abraxis Pharmaceutical runs 11 drugs, 11 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lidocaine | none listed | 2 |
| Sodium chloride | none listed | 0 |
| Furosemide | none listed | 2 |
| Heparin | none listed | 5 |
| Clindamycin | none listed | 0 |
| Zinc sulfate | none listed | 0 |
| Clindamycin phosphate | none listed | 0 |
| Heparin sodium | none listed | 3 |
| Chromic chloride | none listed | 0 |
| Cupric sulfate | none listed | 0 |
| Manganese sulfate anhydrous | none listed | 0 |
A route B row is one company at one target.